Biocon Q2 Results: Profit soars 428% YoY to Rs 85 crore on strong biosimilar and generics growth
Biocon Group reported a strong Q2 FY26 with a 20% year-on-year increase in operating revenue to Rs 4,296 crore, driven by biosimilars and generics. Net profit surged 428% to Rs 85 crore, boosted by debt settlement and strategic partnerships for affordable insulin access in the US. The company also inaugurated its first US OSD manufacturing facility and commenced Semaglutide filings.
Biocon Group reported a strong Q2 FY26 with a 20% year-on-year increase in operating revenue to Rs 4,296 crore, driven by biosimilars and generics. Net profit surged 428% to Rs 85 crore, boosted by debt settlement and strategic partnerships for affordable insulin access in the US. The company also inaugurated its first US OSD manufacturing facility and commenced Semaglutide filings.
What's Your Reaction?
:max_bytes(150000):strip_icc()/GettyImages-2187410260-5afe56694791404f99c253dd8d5abe6a.jpg?#)
